Thursday preview: AstraZeneca and Unilever report
AstraZeneca and Unilever will take centre stage Thursday when the FTSE 100 companies reveal their first quarter results.
AstraZeneca and Unilever will take centre stage Thursday when the FTSE 100 companies reveal their first quarter results.
Drug giant AstraZeneca is expected to report an earnings per share of $1.41, compared to the group's consensus of $1.37, according to Panmure Research.
"The stock has significantly outperformed the market this year and investors should look to taking profits as we do not expect these results to be catalysts to further outperformance," the broker said, reiterating a 'hold' recommendation.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Earlier this month, the biopharmaceutical business announced positive results from a study of fostamatinib, an oral drug being developed for the treatment of rheumatoid arthritis.
In the phase III study, designed to assess the efficacy and safety of fostamatinib, the drug achieved a "statistically significant improvement" in the ACR20 [American College of Rhematology] response rate in patients compared to a placebo.
Meanwhile, Panmure anticipates Unilever will deliver a healthy 6.0% like-for-like growth in the first quarter, slightly ahead the 5.6% consensus.
The consumer goods company last year reported its highest growth quarter with an 8.4% like-for-like growth.
Panmure said an unseasonably cold European March was likely to have affected ice-cream sales but an early Easter will provide some benefit.
"Unilever remains our favourite large cap stock given its ability to deliver superior growth from its attractive emerging market positions, although we would like to see it find more acquisitions given the successes of Alberto Culver and Kalina," the analyst said. It recommended a 'buy' rating.
Thursday April 25th
INTERNATIONAL ECONOMIC ANNOUNCEMENTS
Bloomberg Consumer Confidence (US) (14:45)
Continuing Claims (US) (13:30)
Initial Jobless Claims (US) (13:30)
Q3
AstraZeneca, Banco Santander SA, Polski Koncern Naftowy Orlen S.A. GDR(Reg S), Unilever
GMS
European Assets Trust NV (Regd)
IMSS
Admiral Group, Aer Lingus Group, AZ Electronic Materials SA (DI), British American Tobacco, Namakwa Diamonds Ltd. (DI), Playtech Ltd., Senior
AGMS
Acencia Debt Strategies Ltd., Admiral Group, Aggreko, ARC Capital Holdings Ltd, AstraZeneca, Barclays, Berendsen, Biome Technologies. BlackRock World Mining Trust, British American Tobacco, COLT Group SA, Croda International, Dialight, DP World Limited, Electric Word, EP Global Opportunities Trust, European Assets Trust NV (Regd), Filtrona PLC, Forbidden Technologies, Guaranty Trust Bank GDR (Reg S), International Personal Finance, JPMorgan Claverhouse Inv Trust, Kimberly Enterprises NV, Kolar Gold Ltd., Powerflute Oyj (DI), Premier Foods, SpaceandPeople, Synety Group, Taylor Wimpey, Tomco Energy, Volkswagen AG, Wolfson Microelectronics
UK ECONOMIC ANNOUNCEMENTS
GDP (Preliminary) (09:30)
Index of Services (09:30)
FINAL DIVIDEND PAYMENT DATE
Anglo American, Maintel Holdings, Shore Capital Group Ltd.
Q1
AstraZeneca, Banco Santander SA, Polski Koncern Naftowy Orlen S.A. GDR(Reg S), Unilever
RD
-
Pensioners ‘running down larger pots’ to avoid inheritance tax as rule change loomsChanges to inheritance tax (IHT) rules for unused pension pots from April 2027 could trigger an ‘exodus of large defined contribution pension pots’, as retirees spend their savings rather than leave their loved ones with an IHT bill.
-
Why do experts think emerging markets will outperform?Emerging markets were one of the top-performing themes of 2025, but they could have further to run as global investors diversify
